» Articles » PMID: 37566052

DCUN1D1 Is an Essential Regulator of Prostate Cancer Proliferation and Tumour Growth That Acts Through Neddylation of Cullin 1, 3, 4A and 5 and Deregulation of Wnt/Catenin Pathway

Overview
Journal Cells
Publisher MDPI
Date 2023 Aug 11
PMID 37566052
Authors
Affiliations
Soon will be listed here.
Abstract

Defective in cullin neddylation 1 domain containing 1 (DCUN1D1) is an E3 ligase for the neddylation, a post-translational process similar to and occurring in parallel to ubiquitin proteasome pathway. Although established as an oncogene in a variety of squamous cell carcinomas, the precise role of DCUN1D1 in prostate cancer (PCa) has not been previously explored thoroughly. Here, we investigated the role of DCUN1D1 in PCa and demonstrated that DCUN1D1 is upregulated in cell lines as well as human tissue samples. Inhibition of DCUN1D1 significantly reduced PCa cell proliferation and migration and remarkably inhibited xenograft formation in mice. Applying both genomics and proteomics approaches, we provide novel information about the DCUN1D1 mechanism of action. We identified CUL3, CUL4B, RBX1, CAND1 and RPS19 proteins as DCUN1D1 binding partners. Our analysis also revealed the dysregulation of genes associated with cellular growth and proliferation, developmental, cell death and cancer pathways and the WNT/β-catenin pathway as potential mechanisms. Inhibition of DCUN1D1 leads to the inactivation of β-catenin through its phosphorylation and degradation which inhibits the downstream action of β-catenin, reducing its interaction with Lef1 in the Lef1/TCF complex that regulates Wnt target gene expression. Together our data point to an essential role of the DCUN1D1 protein in PCa which can be explored for potential targeted therapy.

Citing Articles

MAFG-DT promotes prostate cancer bone metastasis through activation of the Wnt/β-catenin pathway.

Wang C, Zhou Z, Ye Y, Zhou L, Wang J, Zhang Z Front Oncol. 2024; 14:1461546.

PMID: 39735608 PMC: 11671513. DOI: 10.3389/fonc.2024.1461546.


TCF4 as a potential prognostic biomarker and an anticancer target in gastric cancer.

Wang H, Sahu A, Chuong M, Li R Transl Cancer Res. 2024; 13(9):5073-5086.

PMID: 39430834 PMC: 11483414. DOI: 10.21037/tcr-24-1290.


Androgen Signaling in Prostate Cancer: When a Friend Turns Foe.

Pandey S, Sabharwal U, Tripathi S, Mishra A, Yadav N, Dwivedi-Agnihotri H Endocr Metab Immune Disord Drug Targets. 2024; 25(1):37-56.

PMID: 38831575 DOI: 10.2174/0118715303313528240523101940.


Inhibition of DCUN1D1 attenuates periodontitis by suppressing NF-κB signaling.

Zou L, Su Z, Pan C, Xie H, Li S, Qin J Odontology. 2024; 112(4):1266-1273.

PMID: 38393516 DOI: 10.1007/s10266-024-00902-8.


Deciphering the role of neddylation in tumor microenvironment modulation: common outcome of multiple signaling pathways.

Liu D, Che X, Wu G Biomark Res. 2024; 12(1):5.

PMID: 38191508 PMC: 10773064. DOI: 10.1186/s40364-023-00545-x.

References
1.
Kumar S, Yoshida Y, Noda M . Cloning of a cDNA which encodes a novel ubiquitin-like protein. Biochem Biophys Res Commun. 1993; 195(1):393-9. DOI: 10.1006/bbrc.1993.2056. View

2.
Paccez J, Vasques G, Correa R, Vasconcellos J, Duncan K, Gu X . The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene. 2012; 32(6):689-98. PMC: 4078100. DOI: 10.1038/onc.2012.89. View

3.
Soucy T, Smith P, Milhollen M, Berger A, Gavin J, Adhikari S . An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009; 458(7239):732-6. DOI: 10.1038/nature07884. View

4.
Mi H, Muruganujan A, Ebert D, Huang X, Thomas P . PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. Nucleic Acids Res. 2018; 47(D1):D419-D426. PMC: 6323939. DOI: 10.1093/nar/gky1038. View

5.
Steinhart Z, Angers S . Wnt signaling in development and tissue homeostasis. Development. 2018; 145(11). DOI: 10.1242/dev.146589. View